Search details
1.
Real-world study of next-generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan.
Cancer Sci
; 114(6): 2524-2533, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-36751989
2.
Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
Value Health
; 26(1): 64-70, 2023 01.
Article
in English
| MEDLINE | ID: mdl-35985941
3.
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
Future Oncol
; 19(14): 961-973, 2023 May.
Article
in English
| MEDLINE | ID: mdl-37306090
4.
Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data.
Future Oncol
; 18(17): 2063-2074, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-35232230
5.
Reliability, validity and important difference estimates for the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18).
Future Oncol
; 17(30): 3951-3964, 2021 Oct.
Article
in English
| MEDLINE | ID: mdl-34287020
6.
CostEffectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)Positive NonSmallCell Lung Cancer in Sweden.
Appl Health Econ Health Policy
; 21(4): 661-672, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37173513
7.
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Lancet Respir Med
; 11(4): 354-366, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36535300
8.
Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study.
Target Oncol
; 17(1): 25-33, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34964940
9.
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.
Lung Cancer
; 174: 146-156, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36410210
10.
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC.
JTO Clin Res Rep
; 3(10): 100406, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-36247019
11.
The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden.
Pharmacoeconomics
; 39(8): 941-952, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34080140
12.
Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan.
JTO Clin Res Rep
; 2(3): 100136, 2021 Mar.
Article
in English
| MEDLINE | ID: mdl-34589999
13.
The burden of family caregiving in the United States: work productivity, health care resource utilization, and mental health among employed adults.
J Multidiscip Healthc
; 10: 437-444, 2017.
Article
in English
| MEDLINE | ID: mdl-29255364
14.
The burden of selected cancers in the US: health behaviors and health care resource utilization.
Cancer Manag Res
; 9: 721-730, 2017.
Article
in English
| MEDLINE | ID: mdl-29238222
Results
1 -
14
de 14
1
Next >
>>